PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8537251-8	1995	Because GnRH antagonist-antiandrogen treatment can protect stem spermatogonial survival and/or function in the rat from cyclophosphamide-induced damage, if the same principles are applicable in human, hormonal pretreatment should be useful for preventing the prolonged azoospermia caused by chemotherapy with cyclophosphamide-containing protocols.	Cyclophosphamide	120-136	gonadotropin releasing hormone 1	Rattus norvegicus	8-12	
17983495-1	2007	OBJECTIVE: To investigate the effects of gonadotropin releasing hormone agonist (GnRH-a) and antagonist (GnRH-ant) on cyclophosphamide (CTX)-induced ovarian damage in rats.	Cyclophosphamide	118-134	gonadotropin releasing hormone 1	Rattus norvegicus	81-85	
17983495-1	2007	OBJECTIVE: To investigate the effects of gonadotropin releasing hormone agonist (GnRH-a) and antagonist (GnRH-ant) on cyclophosphamide (CTX)-induced ovarian damage in rats.	Cyclophosphamide	118-134	gonadotropin releasing hormone 1	Rattus norvegicus	105-109	
9240625-9	1997	The GnRH-a and chemotherapy cotreatment may be also suggested for young women treated by cyclophosphamide pulse therapy or other gonadotoxic treatments for systemic lupus erythematosus, organ transplantation and other autoimmune diseases.	Cyclophosphamide	89-105	gonadotropin releasing hormone 1	Rattus norvegicus	4-10	
8537251-8	1995	Because GnRH antagonist-antiandrogen treatment can protect stem spermatogonial survival and/or function in the rat from cyclophosphamide-induced damage, if the same principles are applicable in human, hormonal pretreatment should be useful for preventing the prolonged azoospermia caused by chemotherapy with cyclophosphamide-containing protocols.	Cyclophosphamide	309-325	gonadotropin releasing hormone 1	Rattus norvegicus	8-12	
20482803-0	2010	Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide.	Cyclophosphamide	113-129	gonadotropin releasing hormone 1	Rattus norvegicus	60-64	
2142603-0	1990	Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.	Cyclophosphamide	89-105	gonadotropin releasing hormone 1	Rattus norvegicus	29-66	
2142603-1	1990	The possible protective effect of an agonist of luteinising hormone-releasing hormone (LH-RH) against the ovarian damage caused by cyclophosphamide was investigated in rats.	Cyclophosphamide	131-147	gonadotropin releasing hormone 1	Rattus norvegicus	48-85	
2142603-1	1990	The possible protective effect of an agonist of luteinising hormone-releasing hormone (LH-RH) against the ovarian damage caused by cyclophosphamide was investigated in rats.	Cyclophosphamide	131-147	gonadotropin releasing hormone 1	Rattus norvegicus	87-92	
2142603-9	1990	Thus, the treatment with D-Trp6-LH-RH microcapsules before and during chemotherapy prevented the ovarian injury inflicted by cyclophosphamide.	Cyclophosphamide	125-141	gonadotropin releasing hormone 1	Rattus norvegicus	32-37	
25848306-1	2015	OBJECTIVE: The aim of the study reported here was to investigate the protective effect of gonadotropin-releasing hormone analog (GnRHa) against cyclophosphamide (CTX)-induced gonadotoxicity.	Cyclophosphamide	144-160	gonadotropin releasing hormone 1	Rattus norvegicus	129-134	
19861704-1	2010	The aim of the current study was to examine the effects of gonadotropin-releasing hormone agonist (GnRH-a) and antagonist (GnRH-ant) on the expression of GnRH receptor-I (GnRHR-I) in pituitary and ovaries in cyclophosphamide (CTX) chemotherapeutic rats and to investigate the possible mechanism of interventions of GnRH-a and GnRH-ant in CTX-induced ovarian damage.	Cyclophosphamide	208-224	gonadotropin releasing hormone 1	Rattus norvegicus	59-89	
20117996-1	2010	OBJECTIVE: To study the effects of gonadotroph-releasing hormone (GnRH) agonist (GnRH-a) and GnRH antagonist (GnRH-ant) on cyclophosphamide (CTX)-induced follicle apoptosis in female rats.	Cyclophosphamide	123-139	gonadotropin releasing hormone 1	Rattus norvegicus	35-64	
19861704-1	2010	The aim of the current study was to examine the effects of gonadotropin-releasing hormone agonist (GnRH-a) and antagonist (GnRH-ant) on the expression of GnRH receptor-I (GnRHR-I) in pituitary and ovaries in cyclophosphamide (CTX) chemotherapeutic rats and to investigate the possible mechanism of interventions of GnRH-a and GnRH-ant in CTX-induced ovarian damage.	Cyclophosphamide	208-224	gonadotropin releasing hormone 1	Rattus norvegicus	99-105	
19861704-1	2010	The aim of the current study was to examine the effects of gonadotropin-releasing hormone agonist (GnRH-a) and antagonist (GnRH-ant) on the expression of GnRH receptor-I (GnRHR-I) in pituitary and ovaries in cyclophosphamide (CTX) chemotherapeutic rats and to investigate the possible mechanism of interventions of GnRH-a and GnRH-ant in CTX-induced ovarian damage.	Cyclophosphamide	208-224	gonadotropin releasing hormone 1	Rattus norvegicus	99-103	
19861704-1	2010	The aim of the current study was to examine the effects of gonadotropin-releasing hormone agonist (GnRH-a) and antagonist (GnRH-ant) on the expression of GnRH receptor-I (GnRHR-I) in pituitary and ovaries in cyclophosphamide (CTX) chemotherapeutic rats and to investigate the possible mechanism of interventions of GnRH-a and GnRH-ant in CTX-induced ovarian damage.	Cyclophosphamide	208-224	gonadotropin releasing hormone 1	Rattus norvegicus	123-127	
19861704-1	2010	The aim of the current study was to examine the effects of gonadotropin-releasing hormone agonist (GnRH-a) and antagonist (GnRH-ant) on the expression of GnRH receptor-I (GnRHR-I) in pituitary and ovaries in cyclophosphamide (CTX) chemotherapeutic rats and to investigate the possible mechanism of interventions of GnRH-a and GnRH-ant in CTX-induced ovarian damage.	Cyclophosphamide	208-224	gonadotropin releasing hormone 1	Rattus norvegicus	123-129	
19861704-1	2010	The aim of the current study was to examine the effects of gonadotropin-releasing hormone agonist (GnRH-a) and antagonist (GnRH-ant) on the expression of GnRH receptor-I (GnRHR-I) in pituitary and ovaries in cyclophosphamide (CTX) chemotherapeutic rats and to investigate the possible mechanism of interventions of GnRH-a and GnRH-ant in CTX-induced ovarian damage.	Cyclophosphamide	208-224	gonadotropin releasing hormone 1	Rattus norvegicus	123-127